PR News Wire…. BLUE BELL, Pa., Oct. 31, 2011 /PRNewswire/ — Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), which is advancing synthetic vaccines to fight cancers and infectious diseases, announced today that VGX-3100, its investigational SynCon® vaccine for treating cervical dysplasia and cancer caused by human papillomavirus, was highlighted by Fierce Vaccines as one of 10 […]
Inovio reports sustained immune responses from cervical cancer DNA vaccine
Proactive Investors USA & Canada May 9, 2011 1:06 pm by Deborah Sterescu US-based vaccine maker Inovio Pharmaceuticals (AMEX:INO) reported Monday clinical data that showed the long-term immune responses induced by the company’s DNA vaccine for treating cervical dysplasia and cancer caused by HPV. Human papillomavirus (HPV) is a virus responsible for most cases of […]
Inovio Pharmaceuticals Unveils Needle-free, Contactless Electroporation Technology for DNA Vaccine Delivery
Press Release by Inovio Pharmaceuticals BLUE BELL, Pa., Feb. 7, 2011 /PRNewswire/ — Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that its new generation DNA vaccine delivery technology, which provides the powerful enabling capabilities of electroporation without contacting the […]